Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Beijing's Immunotech Plans to Raise up to $200 Million in Hong Kong IPO

publication date: Sep 5, 2019

Immunotech Biopharm of Beijing has released its initial prospectus for a Hong Kong IPO, an offering expected to raise up to $200 million. The company's lead product, EAL, consists of autologous CD8+ T cells activated and expanded ex vivo. EAL is currently being tested in a China Phase II trial in patients with post-surgical liver cancer. Immunotech, which hopes EAL will be ready for a 2021 launch, is also working on pre-clinical development of nine CAR-T candidates. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China